Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06334900
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-21
Brief Title:
Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ata-GAD
Brief Summary:
Glutamic acid decarboxylase GAD is an enzyme whose function in the body is to decarboxylate glutamate to GABA GAD65 antibodies GAD65Ab have been associated with type-1 diabetes 80 of new-onset patients and various neurological conditions mainly stiff-person syndrome SPSPERM cerebellar ataxia CA limbic encephalitis LE and temporal lobe epilepsy These syndromes all seem to result from a reduced transmission of GABA These neurological conditions are rare and can cause symptoms like confusion memory loss muscle stiffness muscle spasms behavioural disorders and pharmacoresistant epilepsy When finding high levels of GAD65-Ab in the serum a cerebrospinal fluid CSF sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None